Pneumococcal vaccination may induce anti-oxidized low-density lipoprotein antibodies that have potentially protective effects against cardiovascular disease

详细信息	查看全文 | 推荐本文 |

• 作者：B. Suthers^a ; P. Hansbro^b ; S. Thambar^a ; M. McEvoy^c ; R. Peel^c ; J. Attia^a ; ^c ; ^{john.attia@newcastle.edu.au}
• 关键词：Pneumococcal vaccine ; Ox-LDL ; Anti-oxLDL antibodies ; Cardiovascular disease
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：8 June, 2012
• 卷：30
• 期：27
• 页码：3983-3985
• 文件大小：235 K

摘要

Many animal and human studies have found an inverse association between anti-oxidized low-density lipoprotein (oxLDL) antibodies (anti-oxLDL) and atherosclerotic burden. Furthermore, anti-oxLDL antibodies have been shown to cause regression of atherosclerotic plaque in mice. Animal studies indicate that the 23-valent pneumococcal vaccine may induce the production of these potentially protective anti-oxLDL antibodies, and human epidemiological studies support their potentially beneficial effect in reducing cardiovascular events. Here we describe the association between self-reported pneumococcal vaccination, vaccination verified by linkage to health records, and anti-pneumococcal antibody titers, and anti-ox-LDL titers in a group of 116 older people. We found a bimodal distribution of anti-oxLDL antibodies, and a significant association between pneumococcal IgG and anti-oxLDL antibody titers that remained after multivariate adjustment for potential confounders (p = 0.04). There was no significant association between self-reported vaccination or vaccination verified by health record linkage and ox-LDL titers, which may be due to reporting error or variability in response to the vaccine. These results support a mechanistic link between pneumococcal vaccination and a potential protective effect on cardiovascular disease, and indicate that self-reported or verified vaccine status may not be sufficient to detect this association.